Business Context and Reporting Period
This Form 8-K Current Report, dated July 31, 2000, details the completion of PerkinElmer, Inc.'s acquisition of NEN Life Sciences, Inc. ("NEN"), a provider of drug discovery products and technologies. The transaction closed on July 31, 2000, making NEN a wholly-owned subsidiary. The report also references PerkinElmer's second-quarter 2000 financial results released on July 20, 2000.
Key Financial Metrics and Transaction Details
- Acquisition Price: Approximately $400 million aggregate purchase price, consisting of $350 million in cash, warrants to purchase 300,000 shares of PerkinElmer common stock, and the assumption of approximately $50 million in NEN indebtedness.
- Financing: The acquisition and debt repayment were financed via $400 million in commercial paper borrowings at a weighted-average interest rate of 7.1%. Management intends to refinance this on a long-term basis.
- Escrow: $22.5 million of cash consideration was placed in escrow to satisfy indemnification obligations.
- Pro Forma Assets (as of April 2, 2000): Total assets increased to $2.21 billion, driven by $348.4 million in pro forma adjustments, primarily $342.9 million in intangible assets (including $348.0 million in goodwill).
- Pro Forma Liabilities: Short-term debt and current portion of long-term debt rose to $745.1 million due to the $400 million financing adjustment.
- Pro Forma Income (Fiscal Year Ended Jan 2, 2000): Combined sales of $1.68 billion; Operating income of $48.0 million; Net income from continuing operations of $(10.7) million due to acquisition-related charges and interest.
- Pro Forma Income (Three Months Ended April 2, 2000): Combined sales of $431.3 million; Operating income of $33.9 million; Net income from continuing operations of $8.4 million.
Material Changes and Accounting Adjustments
The filing treats the Merger as a purchase for accounting purposes. Key material changes include:
- Goodwill and Intangibles: Approximately $348 million of goodwill and $22 million of identifiable intangible assets were recorded for the NEN acquisition. Goodwill is being amortized over 15 years.
- In-Process R&D: A $19 million charge for in-process research and development (IPR&D) was recorded and excluded from pro forma operating results as a nonrecurring item.
- Restructuring: Approximately $10 million in accrued restructuring costs were recorded, related to integration, overhead reduction, and facility consolidation. These actions are expected to occur by mid-2001.
- Asset Write-ups: Adjustments were made to write up NEN's inventory, property, plant, and equipment to fair value, resulting in additional amortization and depreciation expenses in the pro forma statements.
Outlook, Risks, and Management Commentary
PerkinElmer intends to continue NEN's business substantially as conducted prior to the merger but will review assets, operations, and personnel. Alternative plans, including asset transfers or further mergers, may be developed following this review. The pro forma financial information is preliminary; final purchase price allocations depend on ongoing independent valuations. The company notes that the pro forma results do not reflect operating efficiencies or cost savings expected from the integration. A primary risk is the impact of the $400 million commercial paper financing on interest expense until long-term refinancing is secured.
Investor Verification Checklist
- Verify the final purchase price allocation, specifically the valuation of goodwill and intangible assets, once independent appraisals are complete.
- Monitor the timeline and execution of the $10 million restructuring plan and associated cost savings.
- Track the refinancing of the $400 million commercial paper debt to assess long-term interest rate exposure.
- Review the integration progress of NEN's drug discovery products with PerkinElmer's existing portfolio.
- Confirm the impact of the $19 million in-process R&D charge on future R&D capitalization policies.